2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

• December 19, 2002
  Cypress Bioscience, Inc. Announces that Milnacipran is Effective in Animal Model of Fibromyalgia
• December 17, 2002
  Cypress Bioscience, Inc. Milnacipran is Only Compound Shown to Preferentially Block Norepinephrine Uptake in In Vitro Model
• December 10, 2002
  Cypress Bioscience, Inc.’s Milnacipran Significantly Improves Pain and Fatigue in Fibromyalgia Syndrome Patients
• November 13, 2002
  Cypress Bioscience, Inc. Announces Third Quarter 2002 Results
• November 11, 2002
  Cypress Bioscience, Inc. Drug Milnacipran Effective Analgesic for Visceral Pain in Animal Model
• November 8, 2002
  Cypress Bioscience Inc. Drug Milnacipran Shown to Affect Multiple Pain Pathways
• November 6, 2002
  Cypress Bioscience, Inc. Drug Milnacipran Effective in Antidepressant Animal Model
• October 28, 2002
  Milnacipran Effective Analgesic in an Animal Model to Assess Analgesic Efficacy in Persistent Pain
• October 7, 2002
  Milnacipran Pharmacology and Development Program Presented at National Fibromyalgia Research Association Conference
• September 10, 2002
  Cypress Completes Enrollment of Phase II Milnacipran Clinical Trial Results Expected in Early 2003
• September 5, 2002
  Cypress Bioscience, Inc. Establishes Collaboration with Collegium Pharmaceutical Inc. to Develop Second Generation Milnacipran
• August 22, 2002
  Cypress Bioscience Inc. Launches Program to Evaluate Efficacy of Milnacipran in Depressed Mood Associated with Chronic Pain Conditions
• August 21, 2002
  Improved System for Monitoring Pain Presented by Cypress Bioscience Inc. at World Congress on Pain Meeting
• August 20, 2002
  Milnacipran Outperforms SNRI in an Animal Model to Assess Analgesic Efficacy in Chronic Pain
• August 15, 2002
  Cypress Bioscience Announces Second Quarter 2002 Results
• July 9, 2002
  Cypress' Comprehensive Review of the Neuropharmacology of Centrally-Acting Analgesic Medications in Fibromyalgia Syndrome Featured in Rheumatic Disease Clinics of North America
• June 18, 2002
  Cypress Bioscience Featured in invivodata Webconference
• June 14, 2002
  Cypress Bioscience Featured in Fibromyalgia Aware Magazine
• May 15, 2002
  Cypress Bioscience Announces First Quarter 2002 Results
• April 8, 2002
  Cypress Bioscience, Inc. Meets NASDAQ Listing Requirements Resumes Normal Trading Under Symbol CYPB
• April 2, 2002
  Auditors Withdraw "Going Concern Opinion"
• April 1, 2002
  Cypress Bioscience, Inc. Closes $17 Million Financing
• March 26, 2002
  Cypress Bioscience, Inc. Receives Stockholder Approval to Complete a $17 Million Private Placement
• March 11, 2002
  Cypress Bioscience Announces Fourth Quarter and Fiscal Year End 2001 Results
• March 7, 2002
  Nasdaq Agrees to Extend Cypress Bioscience, Inc. Listing on The Nasdaq SmallCap Market
• February 25, 2002
  Cypress Bioscience Launches Phase II Program for Milnacipran in the Treatment of Fibromyalgia Syndrome
• February 21, 2002
  Cypress Bioscience, Inc. Enters Into Agreements for Private Placement of $17 Million
• February 14, 2002
  Cypress’ Comprehensive Review of the Psychopharmacology of Fibromyalgia Syndrome Featured in Psychopharmacology Bulletin
• February 8, 2002
  Cypress Bioscience Names Sabrina Martucci Johnson Interim Chief Financial Officer
• January 29, 2002
  Cypress Bioscience Advances FMS Initiative with the Launch of The Fibromyalgia Resource Center and On-line Patient Registry
• January 24, 2002
  Cypress Bioscience receives Nasdaq delisting notice
• January 7, 2002
  Cypress Bioscience to Begin Phase II Clinical Trial To Treat Fibromyalgia Syndromebromyalgia Syndrome